Free Trial

Traws Pharma (TRAW) 10K Form and Latest SEC Filings 2026

Traws Pharma logo
$1.63 -0.09 (-5.23%)
Closing price 04:00 PM Eastern
Extended Trading
$1.63 0.00 (0.00%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Traws Pharma SEC Filings & Recent Activity

Traws Pharma (NASDAQ:TRAW) has submitted 497+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form S-3 submitted on May 8, 2026.

Form 4
Traws Pharma, Inc. Reports Ownership Change on Apr. 28, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Traws Pharma Files Current Report on Apr. 15, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Traws Pharma Files Annual Report on Apr. 30, 2026

The 10-K contains Traws Pharma's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Traws Pharma SEC Filing History

Browse Traws Pharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/08/2026 4:03 PM
Traws Pharma (1130598) Filer
Form S-3
Registration statement under Securities Act of 1933  
05/05/2026 5:55 PM
ORBIMED ADVISORS LLC (1055951) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13D/A
04/30/2026 3:35 PM
Traws Pharma (1130598) Filer
Form 10-K/A
04/28/2026 8:41 PM
ORBIMED ADVISORS LLC (1055951) Reporting
OrbiMed Capital GP VIII LLC (1845804) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:47 PM
Traws Pharma (1130598) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
04/15/2026 3:02 PM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/15/2026 7:00 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/08/2026 1:46 PM
Parker Charles Nolan (2125562) Reporting
Traws Pharma (1130598) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/08/2026 1:47 PM
Parker Charles Nolan (2125562) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 3:57 PM
Traws Pharma (1130598) Filer
Form NT 10-K
03/10/2026 6:22 PM
Clarke Trafford (1958857) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:12 PM
Shoemaker Mary Teresa (1813552) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:15 PM
Redfield Robert (2018274) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:16 PM
STOVER JACK E (1203603) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:17 PM
Savchuk Nikolay (2017800) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:18 PM
Pauza Charles David (2018150) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:19 PM
Dukes Iain D. (1681955) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:20 PM
Leaman John Harold (1586657) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 6:21 PM
CAUTREELS WERNER (1237419) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 7:42 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 11:36 AM
Squadron Capital Management LLC (2050709) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13G/A
02/12/2026 8:11 AM
Adage Capital Management, L.P. (1535978) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13G
02/11/2026 8:44 AM
Ayrton Capital LLC (1698148) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13G/A
01/26/2026 7:30 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/16/2026 3:47 PM
Chernett Jorey (2042077) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13G
01/13/2026 6:00 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/17/2025 5:00 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2025 5:20 PM
Shoemaker Mary Teresa (1813552) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:21 PM
CAUTREELS WERNER (1237419) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:22 PM
Clarke Trafford (1958857) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:23 PM
Leaman John Harold (1586657) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:20 PM
STOVER JACK E (1203603) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:14 PM
Savchuk Nikolay (2017800) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:15 PM
Redfield Robert (2018274) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:16 PM
Pauza Charles David (2018150) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 5:17 PM
Dukes Iain D. (1681955) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 4:00 PM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/28/2025 3:30 PM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2025 5:53 PM
Leaman John Harold (1586657) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 8:07 AM
Adage Capital Management, L.P. (1535978) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13G/A
11/13/2025 6:30 AM
Traws Pharma (1130598) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
The system holding the dollar together is gone… (Ad)

Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every country on Earth to hold U.S. dollars to buy oil. Since then, Saudi Arabia has signed a $7 billion currency swap with China, begun settling oil in digital yuan, and joined China's cross-border payment system, mBridge. With 10-year Treasury yields pushing toward the 4.4% danger line and global dollar demand in retreat, gold is being repriced. There's one asset that still trades at a steep discount to gold's current price - a rare opportunity to leverage the metal's continued rise.tc pixel

Learn how to position ahead of the dollar's continued decline
11/13/2025 6:01 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 4:03 PM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2025 7:03 PM
Shoemaker Mary Teresa (1813552) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 7:04 PM
Clarke Trafford (1958857) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 7:05 PM
STOVER JACK E (1203603) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 7:06 PM
CAUTREELS WERNER (1237419) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 7:07 PM
Dukes Iain D. (1681955) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 7:08 PM
Pauza Charles David (2018150) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 7:09 PM
Redfield Robert (2018274) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 7:10 PM
Savchuk Nikolay (2017800) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/14/2025 6:01 PM
Leaman John Harold (1586657) Reporting
Traws Pharma (1130598) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/14/2025 6:03 PM
Leaman John Harold (1586657) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/14/2025 6:00 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/08/2025 3:19 PM
Traws Pharma (1130598) Filer
Form DEFA14A
10/08/2025 3:24 PM
Traws Pharma (1130598) Filer
Form ARS
10/08/2025 3:16 PM
Traws Pharma (1130598) Filer
Form DEF 14A
10/06/2025 6:00 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/19/2025 2:04 PM
Squadron Capital Management LLC (2050709) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13G
09/12/2025 3:33 PM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/18/2025 6:01 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 6:00 AM
Traws Pharma (1130598) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/14/2025 6:01 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/03/2025 4:08 PM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/30/2025 5:31 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2025 4:59 PM
Clarke Trafford (1958857) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025 4:50 PM
CAUTREELS WERNER (1237419) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025 4:52 PM
Shoemaker Mary Teresa (1813552) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025 4:54 PM
STOVER JACK E (1203603) Reporting
Traws Pharma (1130598) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 6:01 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/27/2025 7:01 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2025 7:00 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025 4:26 PM
Ikarian Capital, LLC (1778253) Filed by
Traws Pharma (1130598) Subject
Form SCHEDULE 13G/A
05/15/2025 6:00 AM
Traws Pharma (1130598) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Traws Pharma SEC Filings - Frequently Asked Questions

Traws Pharma (TRAW) has submitted 497+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Traws Pharma's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form S-3 submitted on May 8, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:TRAW) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners